
Altrius Global Dividend ETF Altrius Global Divid ETF
Altrius Global Dividend ETF Altrius Global Divid ETF (DIVD) Price & Chart
DIVD ETF Chart & Stats
- Day’s Range
- $45.92 - $46.13
- 52-Week Range
- $36.53 - $46.76
- Previous Close
- $45.40
- Volume
- 1,138
- Average Volume (3M)
- 6,741
- AUM
- 27.62M
- NAV
- 46.14
- Expense Ratio
- 0.49%
- Holdings Count
- 65
- Beta
- 0.49
- Inception Date
- Sep 29, 2022
- Last Dividend Ex-Date
- Oct 28, 2026
- Dividend Yield
- (2.64%)
- Shares Outstanding
- 600,000
- Standard Deviation
- N/A
ETF Overview
Altrius Global Dividend ETF Altrius Global Divid ETF
The Altrius Global Dividend ETF (Ticker: DIVD) is a distinguished investment fund designed for those seeking robust income opportunities from global markets. With a specialized focus on high dividend yield, DIVD stands out in the niche category of Broad-based High Dividend Yield ETFs. This fund is strategically crafted to target companies across the globe that are known for their strong dividend-paying capacity, thereby offering investors an attractive income stream while diversifying their portfolio internationally. By investing in a wide array of sectors and regions, the Altrius Global Dividend ETF aims to capture the benefits of global dividend growth while mitigating risks associated with single-market exposure. This makes it an ideal choice for investors who are not only seeking consistent income but also looking to tap into the growth potential of international dividend-paying stocks. With DIVD, you gain access to a thoughtfully curated selection of global equities that prioritize shareholder returns through dividends, providing a powerful combination of income and growth potential in one comprehensive fund.
- Asset Class
- Equity
- Region
- Global
- Issuer
- Altrius
- Index Tracked
- No Underlying Index
- Ticker Symbol
- DIVD
DIVD ETF News



AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s TREVI-OC-02 study is testing torvutatug samrotecan with bevacizumab as first-line maintenance treatment for advanced ovarian, fallopian

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s Phase 3 MATTERHORN-CN study is testing treatment for Chinese patients with operable gastric and gastroesophageal junction
DIVD ETF FAQ
What was DIVD’s price range in the past 12 months?
What is the AUM of DIVD?
Is DIVD overvalued?
Does DIVD pay dividends?
How many shares outstanding does DIVD have?
DIVD ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| TMToyota Motor Corp Ltd Ord | 2.52% |
| CGEMYCapgemini Se Unsponsored ADR | 2.48% |
| AZNAstraZeneca plc | 2.43% |
| MURGYMunchener Ruckversicherungs-Gesellschaft Aktiengesellschaft Unsponsored ADR | 2.36% |
| BTIBritish American Tobacco | 2.35% |
| RBGLYReckitt Benckiser Group Plc-Adr | 2.35% |
| NXPINXP Semiconductors | 2.32% |
| RHHBYRoche Holding AG | 2.26% |
| NSRGYNestle SA Reg Shs. | 2.24% |
| SNYSanofi SA | 2.21% |
| Total | 23.52% |










